Q1 2025 EPS Estimates for Option Care Health, Inc. Lifted by Barrington Research (NASDAQ:OPCH)

Option Care Health, Inc. (NASDAQ:OPCH) – Stock analysts at Barrington Research increased their Q1 2025 earnings estimates for Option Care Health in a research report issued on Wednesday, April 24th. Barrington Research analyst M. Petusky now forecasts that the company will post earnings per share of $0.30 for the quarter, up from their previous forecast of $0.26. Barrington Research has a “Outperform” rating and a $38.00 price objective on the stock. The consensus estimate for Option Care Health’s current full-year earnings is $1.13 per share. Barrington Research also issued estimates for Option Care Health’s Q4 2025 earnings at $0.37 EPS and FY2026 earnings at $1.55 EPS.

Separately, Jefferies Financial Group raised their target price on Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a report on Monday, March 4th.

Option Care Health Trading Down 2.1 %

Shares of NASDAQ OPCH opened at $29.29 on Thursday. The company has a current ratio of 1.77, a quick ratio of 1.33 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $5.09 billion, a PE ratio of 19.27, a PEG ratio of 1.74 and a beta of 1.22. Option Care Health has a twelve month low of $24.23 and a twelve month high of $35.74. The stock has a fifty day simple moving average of $32.04 and a 200-day simple moving average of $31.50.

Option Care Health (NASDAQ:OPCH) last posted its earnings results on Tuesday, April 23rd. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The firm had revenue of $1.15 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter last year, the firm earned $0.21 EPS. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis.

Insiders Place Their Bets

In related news, Director Harry M. Jansen Kraemer, Jr. acquired 35,000 shares of Option Care Health stock in a transaction dated Monday, February 26th. The shares were acquired at an average cost of $31.55 per share, for a total transaction of $1,104,250.00. Following the completion of the purchase, the director now owns 269,528 shares in the company, valued at $8,503,608.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.64% of the stock is owned by company insiders.

Institutional Trading of Option Care Health

Several hedge funds have recently added to or reduced their stakes in OPCH. Principal Securities Inc. purchased a new stake in Option Care Health during the 4th quarter worth about $27,000. Parallel Advisors LLC raised its position in shares of Option Care Health by 130.2% during the 4th quarter. Parallel Advisors LLC now owns 845 shares of the company’s stock worth $28,000 after acquiring an additional 478 shares in the last quarter. TFO Wealth Partners LLC raised its position in shares of Option Care Health by 24,625.0% during the 4th quarter. TFO Wealth Partners LLC now owns 989 shares of the company’s stock worth $33,000 after acquiring an additional 985 shares in the last quarter. Park Place Capital Corp lifted its stake in Option Care Health by 48.4% during the first quarter. Park Place Capital Corp now owns 1,140 shares of the company’s stock worth $38,000 after purchasing an additional 372 shares during the last quarter. Finally, First Horizon Advisors Inc. acquired a new position in Option Care Health in the third quarter valued at approximately $37,000. Institutional investors and hedge funds own 98.05% of the company’s stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.